KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Accumulated Depreciation (2016 - 2018)

Arbutus Biopharma's Accumulated Depreciation history spans 11 years, with the latest figure at $11.1 million for Q1 2023.

  • For Q1 2023, Accumulated Depreciation rose 13.99% year-over-year to $11.1 million; the TTM value through Mar 2023 reached $11.1 million, up 13.99%, while the annual FY2022 figure was $10.8 million, N/A changed from the prior year.
  • Accumulated Depreciation for Q1 2023 was $11.1 million at Arbutus Biopharma, up from $10.8 million in the prior quarter.
  • Across five years, Accumulated Depreciation topped out at $11.1 million in Q1 2023 and bottomed at $8.9 million in Q3 2021.
  • The 3-year median for Accumulated Depreciation is $10.1 million (2022), against an average of $10.2 million.
  • The largest YoY upside for Accumulated Depreciation was 13.99% in 2023 against a maximum downside of 13.99% in 2023.
  • A 3-year view of Accumulated Depreciation shows it stood at $8.9 million in 2021, then grew by 20.74% to $10.8 million in 2022, then increased by 3.09% to $11.1 million in 2023.
  • Per Business Quant, the three most recent readings for ABUS's Accumulated Depreciation are $11.1 million (Q1 2023), $10.8 million (Q4 2022), and $10.1 million (Q2 2022).